Antibody-Protein Conjugate (APC) Formulation and QC

The contract involves the development and production of antibody-protein conjugates for in vivo applications, requiring precise conjugation of monoclonal antibodies with functional effector proteins to ensure targeted biological activity. The scope includes formulation optimization to maintain structural integrity and biological efficacy under physiological conditions, with attention to factors such as pH, buffer composition, and storage stability. Rigorous quality control protocols must be implemented to verify purity through analytical methods like HPLC and CE, assess stability under accelerated and real-time conditions, and confirm sterility and absence of endotoxins to meet regulatory standards for therapeutic use. All work must be performed in compliance with applicable cGMP guidelines to ensure product consistency and safety. Performance is expected to be completed at the designated location in Bethesda, Maryland, with a submission deadline set for August 6, 2026. The contract is classified as a subcontract under NAICS code 325412, indicating pharmaceutical and medicine manufacturing, and is issued by the National Institutes of Health under the Department of Health and Human Services. While no set-aside provisions are specified, the requirement reflects a high-complexity biopharmaceutical initiative demanding expertise in biologics development, advanced analytical characterization, and validated manufacturing processes to support clinical translation.